In this article, we will take a look at 7 Oversold European Stocks to Buy.
European equities fell on March 27 while oil prices remained high, as concerns about the impact of conflict in the Middle East persisted despite US President Donald Trump’s decision to extend the deadline for renewed aerial strikes on Iranian energy facilities until April 6. The Euro Stoxx 50 is down more than 1.3%, and Germany’s DAX is down more than 1.5%.
Against this context, oil prices stayed persistently high at the close of a volatile trading week. The Brent crude futures contract, which expires in May, was recently up 2.6% at $104.53 a barrel, reversing much of the earlier decline and remaining comfortably above pre-war levels.
Expectations have risen that the European Central Bank will be obliged to consider increasing its interest rates in the coming months, a view bolstered by statements from certain ECB governors the previous week.
ECB President Christine Lagarde has suggested that financial markets might be underestimating the scale of the energy crisis, a situation that’s beginning to ripple through the world’s economies. She pointed out that Europe could be particularly vulnerable, given its reliance on energy markets and essential materials like helium, a key component in semiconductor production. Lagarde further indicated that the repercussions could be felt for years, with a slow and steady economic rebound expected.
Our Methodology
For this list, we used stock screeners to identify US-listed European stocks with a Relative Strength Index (RSI) below 30. These stocks are widely held by hedge funds and followed by analysts.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
7. Qiagen N.V. (NYSE:QGEN)
Qiagen N.V. (NYSE:QGEN) ranks among the oversold European stocks to buy. On March 13, Deutsche Bank upgraded Qiagen N.V. (NYSE:QGEN) to Buy from Hold, maintaining a $54 price target on the company’s shares. The firm stated that Qiagen’s stock had declined over 30% since late January’s M&A stories and accompanying downgrade, essentially pricing out any buyout premium.
According to the firm, the company’s 2026 outlook is back-end heavy, which is common among Diagnostics and Life Sciences competitors and is due in part to mechanical impacts reasonably reflected in current consensus estimates.
Qiagen N.V. (NYSE:QGEN) also outlined its strategy at the Barclays 28th Annual Global Healthcare Conference on March 10, emphasizing sustainable development objectives in the midst of a CEO transition.
Despite macroeconomic challenges and the temporary impact of discontinued products such as NeuMoDx, the company reiterated its 5% full-year growth estimate. Growth is likely to improve in the second half, boosted by the introduction of new sample-preparation products that could add up to 200 basis points to results.
Qiagen N.V. (NYSE:QGEN), based in the Netherlands, is a global leader in Sample-to-Insight solutions. The company provides technologies for extracting and analyzing DNA, RNA, and proteins from various samples.
